Anti Cd 20 Ocrevus denied for failing step therapy by Humana?

Humana's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Ocrevus Under Step Therapy — and Why This Is Appealable

Step therapy (also called "fail-first") requires patients to try and document failure of one or more lower-cost or first-line disease-modifying therapies (DMTs) before a plan will cover a higher-cost agent like ocrelizumab (Ocrevus). Humana's step-therapy protocol for multiple sclerosis typically specifies which DMT classes must be tried first. A denial issues when Humana's reviewer determines the required prior steps have not been documented — or that documentation submitted was insufficient to confirm a genuine clinical failure.

This denial type is strongly appealable, particularly because many patients with relapsing MS or primary progressive MS have legitimate clinical reasons why specific prior therapies are inadequate or contraindicated, and because federal and state step-therapy reform laws increasingly require exceptions for clinical appropriateness.

## Your Federal Appeal Rights

• Internal appeal: File within the deadline on your denial notice (commonly 180 days under ERISA §503 or applicable state law).
• External review: Under ACA §2719, you are entitled to independent external review by an accredited IRO after final internal denial. The standard external-review window is approximately four months from the final denial date. An expedited review (72-hour turnaround) is available if your condition makes the standard timeline clinically dangerous.
• Step-therapy exception laws: Many states have enacted step-therapy override statutes requiring plans to grant exceptions when a required prior therapy is contraindicated, caused harm, or is otherwise clinically inappropriate. Ask your neurologist whether your state has such a law and whether your situation qualifies.

## Concrete Steps and Timeline

1. Get the full denial letter. It must name the specific prior therapies Humana requires and cite the coverage/step-therapy policy. 2. Pull Humana's published step-therapy policy for MS DMTs. Note every required step and the criteria for documenting failure or exemption. 3. Compile a prior-therapy timeline (see documentation section below). 4. File the internal appeal with a complete documentation package. 5. If denied internally, escalate immediately to external review — do not let the four-month window lapse.

## Documentation to Gather

• Diagnosis and severity confirmation: Neurologist notes documenting MS subtype (relapsing forms vs. primary progressive), relapse history, MRI lesion burden, and functional status.
• Prior DMT history with dates and outcomes: A chronological list of every disease-modifying therapy previously tried — start date, stop date, reason for discontinuation (inadequate efficacy, intolerance, adverse event, contraindication). Include pharmacy records, infusion records, and chart notes.
• Clinical failure documentation: Lab results, MRI reports, relapse records, or expanded disability status assessments showing disease activity or progression on prior therapy.
• Medical-necessity and exception letter: A letter from your neurologist explaining (a) which required step(s) were tried and failed, or (b) the specific clinical reason(s) why each required prior therapy is not appropriate for you, with reference to applicable AAN or ECTRIMS guideline guidance.
• Prescribing label relevance: For primary progressive MS, note that ocrelizumab has an FDA-approved indication distinct from most earlier-line DMTs — a fact relevant to the clinical necessity argument.

## Criteria-Mapping Structure

Obtain Humana's step-therapy coverage policy in full. For each required step, document your answer:

| Required Prior Step | Your Chart Evidence | |---|---| | [Therapy class 1 required by policy] | Tried [dates], discontinued because [outcome] | | [Therapy class 2 required by policy] | Tried [dates], discontinued because [outcome]; or: contraindicated because [clinical reason] | | Clinical-exception basis (if applicable) | Neurologist letter dated [date] citing [guideline org] |

A well-constructed step-therapy appeal does not argue that Ocrevus is generally superior — it demonstrates precisely that each required prior step was genuinely tried and failed, or that a recognized clinical exception applies.